Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing
Bruker has announced a majority investment in Ridom GmbH, a Next-Generation Sequencing (NGS) bioinformatics solution provider, expanding its microbiology solutions. The strategic collaboration introduces new research-use only NGS-based solutions for epidemiology and hospital-acquired infection (HAI) tracing.
The partnership combines Bruker's IR Biotyper® for rapid, cost-effective HAI outbreak detection with Ridom's SeqSphere+™ NGS bioinformatics software, which enables genomic bacterial strain differentiation and phylogenetic analysis. This creates a unique workflow integrating MALDI Biotyper®-based microbial identification with NGS-based strain determination.
Ridom, a profitable company based in Muenster, Germany, will join Bruker's global microbiology team, though financial details were not disclosed. The collaboration aims to enhance hospital hygiene testing and epidemiological studies through complementary first-line testing and selective NGS reflex testing for confirmation and phylogeny.
Bruker ha annunciato un investimento di maggioranza in Ridom GmbH, un fornitore di soluzioni bioinformatiche per il sequenziamento di nuova generazione (NGS), ampliando le sue soluzioni in microbiologia. La collaborazione strategica introduce nuove soluzioni NGS utilizzabili solo per la ricerca, destinate all'epidemiologia e al tracciamento delle infezioni ospedaliere (HAI).
La partnership combina l'IR Biotyper® di Bruker per la rilevazione rapida ed economica degli focolai di HAI con il software bioinformatico SeqSphere+™ di Ridom, che consente la differenziazione genomica dei ceppi batterici e l'analisi filogenetica. Questo crea un flusso di lavoro unico che integra l'identificazione microbica basata su MALDI Biotyper® con la determinazione dei ceppi basata su NGS.
Ridom, un'azienda redditizia con sede a Muenster, Germania, si unirà al team globale di microbiologia di Bruker, sebbene i dettagli finanziari non siano stati divulgati. La collaborazione mira a migliorare i test di igiene ospedaliera e gli studi epidemiologici attraverso test di prima linea complementari e test riflessivi NGS selettivi per conferma e filogenesi.
Bruker ha anunciado una inversión mayoritaria en Ridom GmbH, un proveedor de soluciones bioinformáticas de secuenciación de nueva generación (NGS), ampliando sus soluciones en microbiología. La colaboración estratégica introduce nuevas soluciones basadas en NGS solo para investigación, destinadas a la epidemiología y al rastreo de infecciones adquiridas en hospitales (HAI).
La asociación combina el IR Biotyper® de Bruker para la detección rápida y rentable de brotes de HAI con el software bioinformático SeqSphere+™ de Ridom, que permite la diferenciación de cepas bacterianas genómicas y el análisis filogenético. Esto crea un flujo de trabajo único que integra la identificación microbiana basada en MALDI Biotyper® con la determinación de cepas basada en NGS.
Ridom, una empresa rentable con sede en Múnster, Alemania, se unirá al equipo global de microbiología de Bruker, aunque los detalles financieros no se han divulgado. La colaboración tiene como objetivo mejorar las pruebas de higiene hospitalaria y los estudios epidemiológicos a través de pruebas de primera línea complementarias y pruebas reflexivas NGS selectivas para confirmación y filogenia.
Bruker는 차세대 시퀀싱(NGS) 생물정보 솔루션 제공업체인 Ridom GmbH에 대한 대다수 투자를 발표하며 미생물학 솔루션을 확장합니다. 이 전략적 협력은 역학 및 병원에서 발생하는 감염(HAI) 추적을 위한 연구 전용 NGS 기반 솔루션을 도입합니다.
이번 파트너십은 HAI 발생 감지를 위한 신속하고 비용 효율적인 Bruker의 IR Biotyper®와 Ridom의 SeqSphere+™ NGS 생물정보 소프트웨어를 결합하여 유전자형 박테리아 변종 구별 및 계통 분석을 가능하게 합니다. 이를 통해 MALDI Biotyper® 기반 미생물 식별과 NGS 기반 변종 결정을 통합하는 독특한 작업 흐름이 생성됩니다.
독일 뮌스터에 본사를 둔 수익성 있는 기업 Ridom은 Bruker의 글로벌 미생물학 팀에 합류할 예정이며, 재정적 세부 사항은 공개되지 않았습니다. 이 협력은 확인 및 계통학을 위한 보완적인 1차 테스트와 선택적인 NGS 반응 테스트를 통해 병원 위생 검사 및 역학 연구를 강화하는 것을 목표로 합니다.
Bruker a annoncé un investissement majoritaire dans Ridom GmbH, un fournisseur de solutions bioinformatiques de séquençage de nouvelle génération (NGS), élargissant ainsi ses solutions en microbiologie. La collaboration stratégique introduit de nouvelles solutions basées sur le NGS uniquement à des fins de recherche, destinées à l'épidémiologie et au traçage des infections nosocomiales (HAI).
Le partenariat combine l'IR Biotyper® de Bruker pour la détection rapide et économique des épidémies de HAI avec le logiciel bioinformatique SeqSphere+™ de Ridom, qui permet la différenciation des souches bactériennes génomiques et l'analyse phylogénétique. Cela crée un flux de travail unique intégrant l'identification microbienne basée sur le MALDI Biotyper® avec la détermination des souches basée sur le NGS.
Ridom, une entreprise rentable basée à Münster, en Allemagne, rejoindra l'équipe mondiale de microbiologie de Bruker, bien que les détails financiers n'aient pas été divulgués. La collaboration vise à améliorer les tests d'hygiène hospitalière et les études épidémiologiques grâce à des tests de première ligne complémentaires et des tests réflexes NGS sélectifs pour la confirmation et la phylogénie.
Bruker hat eine Mehrheitsbeteiligung an Ridom GmbH angekündigt, einem Anbieter von bioinformatischen Lösungen für die Next-Generation Sequencing (NGS), und erweitert damit sein Angebot im Bereich Mikrobiologie. Die strategische Zusammenarbeit führt neue, nur für Forschungszwecke verwendbare NGS-basierte Lösungen zur Epidemiologie und zur Verfolgung von Krankenhausinfektionen (HAI) ein.
Die Partnerschaft kombiniert Brukers IR Biotyper® zur schnellen und kosteneffizienten Erkennung von HAI-Ausbrüchen mit Ridoms SeqSphere+™ NGS-bioinformatischer Software, die die genotypische Differenzierung von Bakterienstämmen und phylogenetische Analysen ermöglicht. Dies schafft einen einzigartigen Workflow, der die MALDI Biotyper®-basierte mikrobiologische Identifikation mit der NGS-basierten Stammestimmung integriert.
Ridom, ein profitables Unternehmen mit Sitz in Münster, Deutschland, wird Teil des globalen Mikrobiologieteams von Bruker, wobei finanzielle Einzelheiten nicht bekannt gegeben wurden. Die Zusammenarbeit zielt darauf ab, die Hygieneuntersuchungen in Krankenhäusern und epidemiologische Studien durch ergänzende Ersttests und selektive NGS-Reflextests zur Bestätigung und Phylogenie zu verbessern.
- Strategic acquisition of profitable company Ridom GmbH enhances diagnostic capabilities
- Expansion into NGS applications opens new market opportunities
- Creation of unique, comprehensive workflow combining multiple testing methods
- Cost-effective solution for hospital infection detection and tracking
- Financial terms of Ridom investment not disclosed
- New solutions to research-use only, not clinical diagnostic applications
Insights
Bruker's majority investment in Ridom GmbH represents a strategic portfolio expansion that strengthens the company's position in the microbiology diagnostics market. Although financial terms weren't disclosed, the announcement that Ridom is profitable suggests this acquisition will likely be accretive rather than dilutive to earnings.
This investment aligns with Bruker's vertical integration strategy, adding complementary NGS bioinformatics capabilities to its established MALDI Biotyper and IR Biotyper platforms. The combination creates a unique workflow solution for hospitals that should increase Bruker's revenue potential per customer and improve competitive differentiation in the hospital infection control market.
The deal appears to be a tuck-in acquisition rather than transformative - appropriate given Bruker's
Bruker's strategic investment in Ridom significantly enhances its capabilities in hospital infection control, addressing a persistent healthcare challenge that costs hospitals billions annually. The combined workflow represents a technical breakthrough in infection surveillance by creating a tiered approach that balances cost-efficiency with precision.
The workflow's design is particularly clever: using the rapid, economical IR Biotyper as first-line screening to rule out outbreaks, reserving expensive NGS sequencing only for confirmation or detailed phylogenetic analysis. This addresses a core limitation in current hospital practice where comprehensive genomic sequencing of all isolates is financially prohibitive.
Ridom's SeqSphere+ software adds critical functionality by enabling cross-platform NGS data analysis, multilocus sequence typing, and real-time transmission detection. The platform-agnostic nature of this software is especially valuable as it allows hospitals flexibility in NGS instrumentation choices while still integrating with Bruker's ecosystem.
Having professor endorsements from both Ridom's founder and a clinical microbiology expert indicates strong scientific credibility. This solution directly addresses hospital antimicrobial stewardship needs and infection control protocols that are increasingly mandated by regulatory requirements, positioning Bruker to capture growth in this essential healthcare market segment.
- Announces majority investment in NGS bioinformatics solution provider Ridom GmbH
- New NGS microbiology solutions for hygiene testing and epidemiological studies
- HAI (Hospital-Acquired Infections) tracing with rapid, cost-effective IR Biotyper® testing, followed by selective NGS reflex testing for confirmation and phylogeny
- Unique workflow with MALDI Biotyper®-based microbial species identification followed by selective NGS-based strain determination and detailed genomic analysis
Professor Dag Harmsen, Managing Director of Ridom GmbH
Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in Muenster,
The new genomic analysis capabilities are immediately beneficial in hospital hygiene and epidemiological analysis by combining complementary, rapid first-line testing with the cost-effective, short time-to-result IR Biotyper for the detection and rule-out of HAI outbreaks, followed by reflex testing on selected samples by NGS for in-depth phylogenetic analysis. Similarly, important samples can be sequenced after species identification with the MALDI Biotyper to gain genomic insights.
Professor Dag Harmsen, the founder and Managing Director of Ridom, said: “We are delighted to become an important part of Bruker´s Microbiology & Infection Diagnostics solutions. Bruker has a track record of bringing innovation to microbiology, and our new strategic collaboration ensures sustainable service for our NGS customers, and creates new opportunities for our significant growth as part of Bruker´s global microbiology team.”
Professor John Rossen, Professor of Personalized Molecular Microbiology in the Department of Medical Microbiology and Infection Control at the University of Groningen and Isala Hospital Zwolle,
Dr. Wolfgang Pusch, President of Bruker´s Microbiology & Infection Diagnostics Division, added: “Since the introduction of our MALDI Biotyper for fast, near-universal microbial identification from cultures, we are committed to bringing innovations to microbiology. The novel, research-use only combination of our IR Biotyper for rapid, cost-effective and strain-specific detection or rule-out of hospital outbreaks, in combination with NGS reflex testing for genomic interpretation with SeqSphere+, provides a unique triage offering for epidemiology and healthcare acquired infection tracing.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411124955/en/
Trade Press & Customer Contact:
Philip Perry
Senior Vice-President, Marketing and Product Management
Bruker Microbiology & Infection Diagnostics Division
T: +49-172-313-7216
E: philip.perry@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
What is the strategic significance of Bruker's investment in Ridom GmbH for BRKR's diagnostic capabilities?
How does the new BRKR NGS workflow enhance hospital infection detection?
What capabilities does Ridom's SeqSphere+ software add to BRKR's diagnostic portfolio?
How will the Bruker-Ridom collaboration impact hospital hygiene testing efficiency?
